Nisa Investment Advisors LLC boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 13.7% during the second quarter, according to its most recent filing with the SEC. The firm owned 7,040 shares of the life sciences company’s stock after buying an additional 850 shares during the period. Nisa Investment Advisors LLC’s holdings in Illumina were worth $1,235,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. American Capital Management Inc. boosted its position in shares of Illumina by 1.6% in the first quarter. American Capital Management Inc. now owns 247,135 shares of the life sciences company’s stock worth $42,171,000 after buying an additional 3,790 shares during the period. Advocacy Wealth Management Services LLC purchased a new position in shares of Illumina during the first quarter worth about $102,000. Mn Services Vermogensbeheer B.V. boosted its position in shares of Illumina by 3.9% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 3,918 shares of the life sciences company’s stock worth $625,000 after buying an additional 147 shares during the period. Nationwide Fund Advisors boosted its position in shares of Illumina by 129.5% in the first quarter. Nationwide Fund Advisors now owns 92,650 shares of the life sciences company’s stock worth $15,810,000 after buying an additional 52,284 shares during the period. Finally, Gemmer Asset Management LLC boosted its position in shares of Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock worth $117,000 after buying an additional 37 shares during the period. 93.91% of the stock is currently owned by institutional investors and hedge funds.
Illumina, Inc. (ILMN) traded down 0.45% during midday trading on Tuesday, hitting $193.92. 545,183 shares of the stock traded hands. Illumina, Inc. has a 52 week low of $119.37 and a 52 week high of $199.95. The stock’s 50-day moving average price is $179.90 and its 200-day moving average price is $174.17. The stock has a market capitalization of $28.31 billion, a P/E ratio of 38.91 and a beta of 0.83.
Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The business had revenue of $662 million during the quarter, compared to analyst estimates of $642.38 million. During the same period last year, the business earned $0.86 EPS. Illumina’s revenue was up 10.3% compared to the same quarter last year. Equities research analysts expect that Illumina, Inc. will post $3.65 EPS for the current fiscal year.
WARNING: “Nisa Investment Advisors LLC Boosts Stake in Illumina, Inc. (NASDAQ:ILMN)” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2017/08/15/illumina-inc-nasdaqilmn-shares-bought-by-nisa-investment-advisors-llc-updated.html.
A number of research analysts recently issued reports on the stock. Zacks Investment Research cut shares of Illumina from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Vetr lowered shares of Illumina from a “strong-buy” rating to a “hold” rating and set a $202.18 target price on the stock. in a research report on Wednesday, August 2nd. Barclays PLC reiterated an “equal weight” rating and set a $150.00 price target on shares of Illumina in a report on Wednesday, August 9th. Canaccord Genuity upgraded shares of Illumina from a “hold” rating to a “buy” rating and lifted their price target for the stock from $170.00 to $215.00 in a report on Monday, August 7th. Finally, BidaskClub upgraded shares of Illumina from a “sell” rating to a “hold” rating in a report on Monday, August 7th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the company. Illumina presently has an average rating of “Hold” and a consensus target price of $177.01.
In related news, EVP Omead Ostadan sold 1,671 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $195.26, for a total value of $326,279.46. Following the transaction, the executive vice president now owns 24,571 shares of the company’s stock, valued at $4,797,733.46. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Charles Dadswell sold 145 shares of the firm’s stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $184.75, for a total transaction of $26,788.75. Following the completion of the transaction, the senior vice president now directly owns 10,791 shares in the company, valued at approximately $1,993,637.25. The disclosure for this sale can be found here. Insiders sold 134,010 shares of company stock valued at $23,946,015 over the last quarter. Company insiders own 1.60% of the company’s stock.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
